Cell and Developmental Biology Commons^™

Targeting Cxcr4 With Ctce-9908 Inhibits Prostate Tumor Metastasis, Donald Wong, Pridvi Kandagatla, Walter Korz, Sreenivasa R. Chinni

Wayne State University Associated BioMed Central Scholarship

Abstract

Background

CXCL12/CXCR4 transactivation of epidermal growth factor family receptors in lipid raft membrane microdomains on cell surface is thought to mediate tumor growth and subsequent development of metastatic disease. CTCE-9908 is a known inhibitor of CXCR4. Herein, we tested the efficacy of CTCE-9908 in inhibiting prostate cancer cell growth, invasion, and metastasis.

Methods

We used a panel ofin vitroassays utilizing human prostate cancer cell lines and anin vivoorthotopic prostate cancer model to assess the anti-tumoral activity of CTCE-9908.

Results

We demonstrated that (a) CTCE-9908 treatment resulted in no significant change in the growth of PC-3 and C4-2B cells; (b) …

Recombinant Interleukin-21 Plus Sorafenib For Metastatic Renal Cell Carcinoma: A Phase 1/2 Study, Shailender Bhatia, Brendan, Marc S. Ernstoff, Michael, Elisabeth I. Heath, Wilson H. Miller Jr, Igor Puzanov, David I. Quinn, Thomas, Peter Vanveldhuizen, Kelly, Jeremy, Rachel, Naomi, Sonia, John A. Thompson

Wayne State University Associated BioMed Central Scholarship

Abstract

Background

Despite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory properties, plus sorafenib, a VEGFR tyrosine kinase inhibitor.

Methods

In this phase 1/2 study, 52 mRCC patients received outpatient treatment with oral sorafenib 400 mg twice daily plus intravenous IL-21 (10–50 mcg/kg) on days 1–5 and 15–19 of each 7-week treatment course. The safety, antitumor activity, pharmacokinetic and pharmacodynamic effects of the combination were …